BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  Lilly Delays Alzheimer’s Submission in Face of Proposed CMS Limitations

  The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.

  February 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact

  The collaboration will focus on expanding targeted protein degradation therapies through the discovery of previously unrecognized molecular glues or monovalent degraders.

  February 3, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  BioSpace Movers & Shakers, Feb. 4

  Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

  February 3, 2022

   · 

  9 min read

   · 

  Alex Keown
• 

  Drug Development

  CRISPR and ViaCyte Dose First Patient in Historic Type 1 Diabetes Trial

  CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.

  February 3, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Deals

  Intellia Broadens CRISPR Capabilities with Pick Up of Rewrite Therapeutics

  On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.

  February 3, 2022

   · 

  2 min read

   · 

  Claudia Beezhold
• 

  Business

  Mersana, Janssen Come Together in Potential $1B ADC Deal

  Janssen will provide its proprietary antibodies for research, while Mersana will contribute its proprietary Dolasynthem platform to target cancers with large unmet medical needs.

  February 3, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Pfizer Alleges Stolen Trade Secrets at Heart of Regor Therapeutics Launch

  Pfizer has filed a lawsuit against execs at Regor Therapeutics after an investigation pointing company trade secrets were used to develop therapeutics at the center of Regor’s partnership with Eli Lilly.

  February 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  COVID-19 Boosters Decrease Mortality by 97 Times and More News

  The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.

  February 3, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  J&J Incurs $610M Charge for Dropped Atopic Dermatitis Program

  J&J said it was terminating development of bermekimab for atopic dermatitis after looking at additional efficacy data.

  February 3, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Early CAR T Patients Still in the Clear 10 Years On

  A new study published in the journal Nature found that two patients with leukemia who were treated with CAR T-cell therapy are still in remission 10 years later.

  February 3, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh